A carregar...
Agomelatine in the Treatment of Major Depressive Disorder: An Assessment of Benefits and Risks
Agomelatine (AGM) was approved for the treatment of major depressive disorder (MDD) in adults by the European Medicines Agency (EMA) in February 2009. It is an analogue of melatonin and features a unique pharmacodynamic profile with agonism on both types of melatonergic receptors (MT1/MT2) and antag...
Na minha lista:
| Publicado no: | Curr Neuropharmacol |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Bentham Science Publishers
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4243030/ https://ncbi.nlm.nih.gov/pubmed/25426008 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2174/1570159X12999140619122914 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|